




AVICANNA™

Innovation in
R&D and cultivation in the
cannabis industry

Avicanna.com

July 2019

Forward-Looking Statement - Confidential



This document and the material contained herein are confidential and are not to be disclosed to the public. This is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. Certain information contained herein and certain oral statements made are forward-looking and relate to Avicanna Inc.'s ("Avicanna") business strategy, product development, timing of product development, events and courses of action. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as "anticipate," "objective," "may," "will," "might," "should," "could," "can," "intend," "expect," "believe," "estimate," "predict," "potential," "plan," "is designed to" or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements about: our expectations regarding our expenses, sales and operations; production, yield and capacity; our future customer concentration; our anticipated cash needs and our estimates regarding our capital requirements and our need for additional financing; our ability to anticipate the future needs of our customers; our plans for future products and enhancements of existing products; our future growth strategy and growth rate; our future intellectual property, research and development, product formulations and business lines; and our anticipated trends and challenges in the markets in which we operate. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which Avicanna will operate in the future, including the demand for our products, anticipated costs and ability to achieve goals and the price of cannabis and cannabis related products. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect.

Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions; the ability to manage our operating expenses, which may adversely affect our financial condition; our ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; weather patterns; market conditions and the demand and pricing for our products; the demand and pricing of cannabis and cannabidiol ("CBD"); security threats, including a loss/ theft of proprietary technology; our relationships with regulatory bodies, our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers' needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; our ability to maintain technological leadership; the impact of technology changes on our products and industry; our failure to develop new and innovative products; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely affect our business; our ability to manage working capital; and our dependence on key personnel. Avicanna is an early stage company with a short operating history; and it may not actually achieve its plans, projections, or expectations. Important factors that could cause actual results to differ materially from Avicanna's expectations include, consumer sentiment towards Avicanna's products and cannabis and cannabis related technology generally, litigation, global economic climate, equipment failures, increase in operating costs, decrease in the price of cannabis and CBD, security threats including a loss or theft of intellectual property, adverse medical findings, government regulations, loss of key employees and consultants, additional funding requirements, changes in laws, technology failures, competition, and failure of counter-parties to perform their contractual obligations. Except as required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation.

Financial Information

All financial information included in this document is unaudited. There is a material risk that the audited financial results will differ significantly from the unaudited financial information presented herein. This document also contains future-oriented financial information and financial outlook information (collectively, "FOFI") about prospective results of operations, future net revenue, share capital, cash flows, and components thereof, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraphs. FOFI contained in this document was made as of the date of this document and was provided for the purpose of providing information about management's current expectations and plans relating to the future. Avicanna disclaims any intention or obligation to update or revise any forward looking statements or FOFI contained in this document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable securities law. Readers are cautioned that the forward looking statements and FOFI contained in this document should not be used for purposes other than for which it is disclosed herein. The forward-looking statements and FOFI contained in this document are expressly qualified by this cautionary statement. Certain information contained herein is based on, or derived from, information provided by independent third-party sources. Avicanna believes that such information is accurate and that the sources from which it has been obtained are reliable. Avicanna cannot guarantee the accuracy of such information, however, and has not independently verified the assumptions on which such information is based. Avicanna does not assume any responsibility for the accuracy or completeness of such information.

Avicanna™ Corporate Highlights



Strategically positioned

- Multi-national operation in North America and Latin America.
- Headquarters located at Johnson and Johnson Innovation (JLABS) in MaRS, the Medical and Related Science Centre in Toronto, Canada

Cultivation and R&D focused on 4 main product categories

- Pharmaceuticals
- Phyto-therapeutics
- CBD Derma-cosmetics
- Cannabis extracts/purified cannabinoids



Manufacturing

- Exclusive manufacturing partnership with Altea Farma a Health Canada GMP certified facility with industrial scale.**

Advanced Cannabinoid Research and Development

- Led by Dr. Christine Allen, interim Dean and Professor of the Faculty of Pharmacy at U of T
 - In collaboration with Avicanna's own 20+ scientists.
- Over 3 years of R&D and intellectual property development in plant biology, extraction, analytical methods, formulation development and pre-clinical analysis.

Clinical Development Collaborations

- With focus on pain, dermatology, and neurology in collaboration with world class institutions including:
 - The University of Toronto, The Hospital for Sick Children (SickKids), The University of West Indies

Organic, Sustainable and Economical Cultivation in Colombia

- Two fully operational cultivation projects in Santa Marta, Colombia, utilizing the optimal climate of the Sierra Nevada Mountains.
 - 410,000 square feet and 24,000 kgs/year - phase 1 capacity*

* Combined and estimated figures for both completed cultivation projects, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S..

** <https://www.alteafarma.com.co/home/>

About Avicanna™

Strategically positioned to be a front runner in the;

- **Development**
- **Manufacturing** and;
- **Commercialization** of plant-derived cannabinoid-based products



RESEARCH AND DEVELOPMENT

Headquartered in **JLABS @ Toronto**, in the **MaRS Centre**, the world's largest urban innovation hub, where Avicanna's scientists conduct research with world-class academic and clinical institutions including the **University of Toronto**.



CULTIVATION

Low cost, industrial scale cultivation and extraction infrastructure through Avicanna's two subsidiaries in Santa Marta, Colombia, focused on **organic and environmentally sustainable practices**.



MANUFACTURING

GMP manufacturing (Health Canada)* and a growing network of global distributors offering our four key plant-derived cannabinoid product categories in;
(i) pharmaceuticals;
(ii) phyto-therapeutics;
(iii) derma-cosmetics; and,
(iv) cannabis extracts and purified cannabinoids.

* <https://www.alteafarma.com.co/home/>

Research and Development (R&D)

A dedication to robust scientific development and evidenced-based clinical approach.



MULTI-NATIONAL SCIENTIFIC TEAM

Collaboration of scientists operating from Toronto, Bogota and Santa Marta, Colombia



EXCLUSIVE RESEARCH AND COLLABORATION AGREEMENT

with Dr. Christine Allen's Research Group (CARG) in the Leslie Dan Faculty of Pharmacy. Services Include;

- **Formulation optimization,**
- **In vitro and in vivo analysis**



FINALIZED PRODUCT OFFERINGS

Fully developed and optimized product lines including Avicanna's proprietary derma-cosmetics and phyto-therapeutics



CLINICAL DEVELOPMENT PROGRAMS

Ongoing efforts to demonstrate product safety and efficacy with world-class clinical partnerships including;

- *SickKids Hospital, Toronto*
- *University of West Indies, Jamaica*
- *Centro de Atención e Investigación Médica (CAIMED), Colombia*





**SATIVA
NATIVA**

AVICANNA™

Cultivation Projects in Santa Marta, Colombia

Dedicated to quality and sustainability



Controlling interests in two Colombian companies focused on commercial cannabis cultivation, **Sativa Nativa** and **Santa Marta Golden Hemp**



60% interest
16 hectares and
220,000 sq ft of
canopy



**SATIVA
NATIVA**

63% interest
2.8 hectares and
70,000 sq ft of
canopy



1

Sun-grown and **environmentally sustainable** practices



2

Competitive **cost advantages** including low cost labour, land and energy



3

Cultivated under **good agricultural** and **collection practices** (GACP)



4

Avicanna's proprietary extraction and purification processes



5

Licenses to cultivate CBD & THC dominant strains for processing and sales in the domestic market and exports



Microclimate of Santa Marta and the Foothills of the Sierra Nevada Mountains



Santa Marta, Magdalena

Optimal environmental conditions

- Proximity to the Caribbean Sea and transport ports
- Fertile lands, clean water and optimal humidity levels
- 12 hours of sunlight year-round



Wind
m/s

5.51



Temp
°C

28.1



Rainfall
mm

545.3



RH
%

66



2 Fully Licensed and Operating Cultivation Subsidiaries



Santa Marta, Colombia

Santa Marta Golden Hemp ("SMGH") and Sativa Nativa ("SN") capacity

Current Capacity	SMGH	SN	Total
Current Cultivation Footprint	220,000 sq. ft.	70,000 sq. ft.	290,000 sq. ft.
Current Annual Capacity	12,000 kg	3,000 kg	15,000 kg

Genetic Registration Status

Status	Strains
Completed Registration	1 Non-Psychoactive Strain (Currently in Cultivation) 3 Psychoactive Strains (Quota Submitted for 1 Psychoactive Strain)
Submitted Applications for Registration	4 Non-Psychoactive Strains 11 Psychoactive Strains
Expected Additional Applications	22 additional applications are expected to be submitted by the end of October 2019

Extraction and Analytical Laboratory Phase 2

Complete integration of post harvest, extraction and isolation utilizing Avicanna's proprietary methodologies with current capacity of 300kg of biomass a day.

Cannabis Testing*

Main Ingredient Testing

- Potency Testing (Cannabinoid Profiling)
- Terpene Profiling
- Moisture Content

Contaminants Test

- Pesticide Analysis
- Mycotoxins Analysis
- Heavy Metals
- Residual Solvents
- Microbiological

Genetic Identification

- Genotype Testing
- Plant Sex Testing



GMP - Manufacturing Partnership

Altea Farmaceutica*



Global GMP Certifications

- INVIMA (Colombia)
- HEALTH CANADA
- ANVISA (Brazil)
- DIGMID (Perú)



GMP Manufacturing of

- Pharmaceutical products
- Phyto-therapeutics products
- Dietary supplement products
- Cosmetic products



Dosage Forms

- Gels, creams, drops, lotions
- Tablets, capsules, pellets, chewable tablets

Altea's Clients:
Pfizer, Novartis, Merck,
GSK, Roche and Myland

* <https://www.alteafarma.com.co/home/>



PURA
EARTH™

Pura Earth™

CBD Derma-Cosmetics

Derma-cosmetic formulations to maintain and improve the health and beauty of the skin.



BEAUTY TREATMENTS



- Anti-Aging Serum
- Anti-Aging Treatment
- Under Eye Treatment
- Dark Spot Treatment

MOISTURIZE & PROTECTION



- Skin Protecting Face Lotion (AM)
- Skin Protecting Face Lotion (PM)
- Skin Protecting Body Lotion

SPECIALIZED CARE



- Clear Skin Treatment
- Intensive Conditioning Treatment

The product mock-ups that appear on this page are not indicative of final products that may be marketed and sold.





PURA
ELEMENTS™

To continue to advance the world
of cannabinoid-based therapies

Pura Elements™

CBD-THC Phyto-therapeutics



Plant-derived cannabinoid-based therapies in a range of CBD and/or THC ratios, doses and forms of delivery.

- USP-NF (pharmaceutical-grade) ingredients
- R&D and product optimization in collaboration with University of Toronto
- Manufactured under GMP certifications including Health Canada and EU
- Supported with bioavailability and pharmacokinetic data
- Products available in isolated cannabinoids or whole plant extracts
- Formulated with organic and sustainable source of natural cannabinoids



The product mock-ups that appear on this page are not indicative of final products that may be marketed and sold.




Pura Elements™

CBD-THC Phyto-therapeutics



Plant-derived cannabinoid-based therapies which undergo rigorous in vitro analysis to ensure product stability, precise delivery and consistency. Formulations are then further validated and optimized post pre-clinical pharmacokinetic studies.



Formulations are optimized in collaboration with the University of Toronto



Oral formulations with **Rapid** and **delayed onset** release profiles



Scientifically designed for **consistent dosing and delivery**



Organic and **sustainable** source of natural cannabis formulated into cannabinoid-based phytotherapies



Innovative and **advanced delivery mechanisms** designed to be **discreet** and **easy to administer**



Topical preparations with **localized** and **deep penetrating** applications



Pharmaceuticals

Pipeline of indication specific products



Pharmaceutical product pipeline following the traditional drug discovery and development process for eventual submission to the applicable government agencies, such as Health Canada or the FDA.

Focus on 6 therapeutic areas and utilizing only isolated Extracts, our intention is to use the isolated Extracts produced by our subsidiaries in Colombia in the pharmaceutical products we will offer.



Dermatology



Pain



Neurology



Oncology



Gastrointestinal



Psychiatry

Current Pipeline in Various Stages of Pre-Clinical and Clinical Development

- Dermatology
- Pain
- Neurology

Clinical Partners

- SickKids Hospital
- University of West Indies
- Centro de Atencion e Investigacion Medica CAIMED S.A.S.
- University of Antioquia



Clinical Development Pipeline



Indication	Cosmetics			Dermatology			Neurology	Pain
Product	AVCST	AVICT	AVAAS	AVCN583601	AVCN585501	AVCN583301	AVCN319301 ^[1]	AVCN467501 ^[2]
Description	Acne topical gel for acne prone skin intended for cosmetics	Eczema topical cream for eczema prone skin intended for cosmetics	Anti-Aging topical cream intended for cosmetics	Epidermolysis Bullosa topical cream intended to be a prescription drug	Acne topical gel intended to be an OTC drug	Eczema topical cream intended to be an OTC drug	Neuropathic Pain sublingual and oral cannabinoid formulations intended for prescription drug	Chronic Pain oral formulations intended for prescription drug
Developmental Stage	Baseline Study Ongoing Expected Completion Sept 2019	Baseline Study Ongoing Expected Completion Sept 2019	Baseline Study Ongoing Expected Completion Sept 2019	Phase II Expected Q4 2019	Phase I Expected Q4 2019	Phase I Expected Q4 2019	Prevalence Study Phase 1 Expected Q4 2019	Pre-clinical Phase 1 Expected Q4 2019
Clinical Institution	CAIMED	CAIMED	CAIMED	Sick Kids Hospital	CAIMED	CAIMED	University of Antioquia & University of West Indies	University of Antioquia

Avicanna Quality Standard (AQS)



Science first

Our **world-class research** and development team's approach to product development includes several stages of *in vitro* and *in vivo* testing to ensure all our products undergo many levels of optimization.

Made for people

Our pharmaceutical product pipeline goes through **well-designed human clinical development**.

Commencing with safety and toxicology to and following up with interventional efficacy studies in order to demonstrate product safety and clinical efficacy across several therapeutic areas.

AQS

Nothing but nature

Our cannabinoids are cultivated naturally, organically, free of herbicides, pesticides and harmful chemicals. We use sustainable growing practices under **Good Agricultural Practices (GAP)** to ensure we support the health of soils and the ecosystems.

Consistency is key

Our products are manufactured to the highest standards for consistent dosing, quality and purity every time. Manufactured with world class **Good Manufacturing Standards (cGMP)** to assure precise delivery of cannabinoids in every product.

Executive Management Team



Aras Azadian, M.Mgmt Chief Executive Officer

Aras brings extensive senior management experience in the biotechnology and financial sectors including his involvement in several successful start-up companies. In addition to his international experience in corporate development, his diverse roles include his previous position as the president of an investment corporation in the cannabis space and former Chief Operating Officer of an oncology company.

Setu Purohit, JD President and Chief Legal Officer

Setu is a lawyer and entrepreneur with experience in complex corporate and legal strategy, contract negotiations, and litigation. Setu has been involved in the cannabis industry for several years as an advocate for patients' rights and advising healthcare professionals, licensed cannabis producers, and other corporate and regulatory stakeholders in Canada and abroad. Prior to co-founding Avicanna, Setu operated his own private practice since 2012.

Dave Sohi, CPA, CA, CBV Chief Financial Officer

Dave received his Chartered Accountant designation in 2008, and following three years in audit and tax he joined the firm's business advisory practice as a manager. Dave's main focus in that group's practice was on mergers and acquisitions and valuation services. In 2010, Dave obtained his Chartered Business Valuator designation, and in 2013 joined Ernst and Young's Transaction Advisory Practice. Following a year with Ernst and Young, Dave opened his own practice where he provided clients with accounting and advisory services.

Dr. Christine Allen, PhD Chief Scientific Officer

Dr. Allen is a Full Professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto. Her research is focused on the design and development of new technologies for the delivery of drugs. Dr. Allen's research has resulted in one hundred thirty peer-reviewed publications on both lipid and polymer-based drug delivery approaches. Dr. Allen has been a Professor at the University of Toronto since 2002.

UNIVERSITY OF TORONTO

Dr. Amza Ali, DM, PhD, MBA Chief Medical Officer

Dr. Ali is certified in Neurologist by the Federation of Royal Colleges of Physicians of the United Kingdom and launched the Epilepsy Society of the Caribbean. Additionally, he has an MBA from Rothman and an MSc in Research Methodology at the Henley Business School in the UK. Business School in the UK.

AMERICAN EPILEPSY SOCIETY

Dr. Justin Grant, PhD, MBA EVP Scientific Affairs

Dr. Grant has over 15 years experience in leading pharmaceutical research in sustained drug release formulations, has held academic positions at UHN and U of T and serves as the research program manager of the STTARR Innovation Centre with Princess Margaret Cancer Centre UHN.

PRINCESS MARGARET CANCER CENTER

Lucas Nosiglia, MFin Chief Agricultural Officer

Lucas has previous experience developing start-up companies in Argentina. In 2013, Lucas started a restaurant called La Causa Nikkei, and operated two locations in Argentina. In 2015, Lucas went on to create a marketing and event agency, Tremending, which focused on providing tailor made experiences for corporate clients. Later, in 2016, Lucas went on to provide business development consulting services for Sanatorios Guemes focused on improving the surgical and pharmaceutical practices of the major medical institution.

Arash Moghani, MBA Chief Technical Officer

Arash began his career at Deloitte as a consultant leading complex strategy and business transformation projects across several sectors globally including banking, technology and healthcare. In 2014, Arash continued his career at the Bank of Montreal, Capital Markets FX Technology department working with diverse teams of stakeholders, gathering business requirements and translating them into comprehensive technology solutions and strategies.

Janeth Mora, PharmD EVP Commercial Development

Experienced pharmaceuticals executive experienced in LATAM including her tenure at INVIMA. Janeth brings executive management experience through roles in Merck and Pfizer, where she held different positions, like Emerging Markets marketing director, as well as regulatory affairs manager in Pfizer Andean region.

Jose Beltran, MBA EVP Corporate Development

Jose offers over 30 years of pharmaceutical industry and health system executive experience across several LATAM countries with Pfizer, Abbott, Aspen and Biotoscana. Industrial engineer and marketing specialist from University of Los Andes and Program for Leadership Development (PLD24) from Harvard University.

Senior Scientific Team



Dr. Frantz Le Devedec, PhD

SVP R&D

Frantz has over 15 years of experience in academic and industrial R&D projects, including material sciences and drug delivery formulations. He is author of over a dozen research papers and patents. His background is in biochemistry, with a PhD in applied polymer chemistry, and expertise in analytical and pharmaceutical sciences.

Dr. Carlos Maldonado, MD

SVP Clinical Development

Carlos has participated in medical and regulatory issues related to the approval and commercialization of several new medicines including Sativex in Colombia. He provides his experience in biotechnology, pharmacovigilance, clinical development through his prior roles as medical directors for companies such as Bayer.

UNIVERSIDAD NACIONAL DE COLOMBIA

Samantha Watt, MSc

VP of Scientific Affairs

Samantha is an experienced scientist with years investigating human and cellular biology. With a Master's of Science from the University of Guelph, she possesses strong communication and laboratory skills that have led her to several publications and conference presentations related to plant gene manipulation and cloning.

Dr. Humberto Reynales, MD, PhD

An epidemiology with a PhD degree in science offers more than 15 years of experience in the pharmaceutical industry including his tenure at Merck & Co and his role as the executive director of Caimed a multinational CRO.

CAIMED

Dr. Mauricio Torres-Pradilla, MD, PhD

Dr. Torres-Pradilla is a dermatologist with a specialization in pediatric dermatology with research emphasis on Atopic Dermatitis, Psoriasis, Epidermolysis Bullosa and Hemangiomas. He is currently Head of Dermatology at Fundación Universitaria de Ciencias de la Salud in Bogota and Dermatologist at Debra Colombia.

FUNDACIÓN UNIVERSITARIA DE CIENCIAS

Dr. Hance Clarke, MD, PhD

Dr. Clarke is the Director of Pain Services and the Medical Director of the Pain Research Unit at the Toronto General Hospital. He is recognized internationally for his research and novel Transitional Pain Program and researching the efficacy of cannabinoids in pain management.

TORONTO GENERAL HOSPITAL

Dr. Alejandro Berlin, MD, MSc

Staff Clinician-Scientist and Radiation Oncologist at the Princess Margaret Cancer Centre. His research focuses on design of innovative clinical trials, translational oncology, research expertise towards novel therapies for patients with cancer.

PRINCESS MARGARET CANCER CENTER

Board of Directors



Aras Azadian, M.Mgmt

Chairman of the Board of Directors and Chief Executive Officer

Aras brings extensive senior management experience in the biotechnology and financial sectors including his involvement in several successful start-up companies. In addition to his international experience in corporate development, his diverse roles include his previous position as the president of an investment corporation in the cannabis space and former Chief Operating Officer of an oncology company.

Setu Purohit, JD

President, Director and Chief Legal Officer

Setu is a lawyer and entrepreneur with experience in complex corporate and legal strategy, contract negotiations, and litigation. Setu has been involved in the cannabis industry for several years as an advocate for patients' rights and advising healthcare professionals, licensed cannabis producers, and other corporate and regulatory stakeholders in Canada and abroad. Prior to co-founding Avicanna, Setu operated his own private practice since 2012.

Dr. Chandrakant Panchal

Lead Director

Dr. Panchal has been the Chief Executive Officer of Axcelon Biopolymers Corp. since 2008, has authored over seventy scientific papers, holds several patents in oncology, diagnostics, biopolymers and microbiology, and is an Adjunct Professor in Chemical and Biochemical Engineering at the University of Western Ontario. Dr. Panchal currently sits on the board of directors of both an oncology company known as Medicenna Therapeutics Corp. (MDNA), and Canadian Oil Recovery and Remediation Inc. (CVR) as well as Pure Global Cannabis Inc. (PURE). Dr. Panchal holds a Master of Science degree in Molecular Biology and a Ph.D. in Biochemical Engineering from the University of Western Ontario.

Giancarlo Davila Char

Director

Mr. Char has experience with sustainable and organic cultivation and production of industrial scale palm oil as well as other agriculture crops such as avocados and coffee beans. In 2017, Mr. Char went on to lead a new branch of his family's business which is dedicated to producing private label oils for national distribution in supermarkets across Colombia. This business unit reached USD\$30,000,000 in sales in 2018. Mr. Char holds a Bachelor of Science in Business Administration from Northeastern University.

Janet Giesselman

Director

A Corporate Director at: Ag Growth International Inc. Omnova Solutions Inc. Twin Disc, Incorporated and at McCain Foods Limited, where she serves as Chair of the Environmental Health & Safety Committee as well as on the Audit and the Compensation and Management committees. Ms. Giesselman retired as the President and General Manager of Dow Oil & Gas, a business unit of The Dow Chemical Company, and has over 30 years of U.S. and international agriculture, energy and specialty and commodity chemicals industry experience in U.S., Europe, Latin America, the Middle East and Asia. Ms. Giesselman holds a B.Sc., Biology from Pennsylvania State University and a Masters in Plant Pathology from the University of Florida.

David Allan White

Director

Mr. White is a director and chair of audit committees of several Toronto Stock Exchange ("TSX") and NASDAQ companies. Mr. White has held several senior financial positions with John Labatt Limited, Lawson Marden Group Inc. and Laidlaw Inc. and most recently as Chief Executive Officer of TransCare Inc., a medical transportation company and as President and Chief Executive Officer of Student Transportation of America, a TSX listed company. In addition to sitting on Avicanna's Board of Directors and chairing the Corporation's audit committee, Mr. White has also been a corporate director and business consultant for First Call Services, a private holding company and advisory firm, since 2012. Mr. White has been a Canadian Chartered Accountant since 1978 and holds a Master of Business Administration degree from the University of Toronto.